Hussein Al Ali: Our recent publication unveils the potential of a ground-breaking therapeutic antibody
Hussein Al Ali, Lecturer in Biomedical Science at Anglia Ruskin University, shared on LinkedIn:
“I’m excited to share with you our recent publication, which represents a significant milestone in our team’s collaborative research efforts with our biopharmaceutical partners, Medannex Ltd.
The article was published in the prestigious journal Oncogene, and unveils the potential of a ground-breaking therapeutic antibody designed to specifically target annexin-A1, a protein implicated in cancer growth and progression.
This publication serves as a testament to the power of collaborative research and underscores our commitment to advancing innovative solutions for cancer treatment.
As we continue to refine and expand our knowledge of MDX-124 in vitro, the phase Ib clinical study of the antibody, called ATTAINMENT, is currently underway to establish the safety and optimum dose of this antibody.
Its clinical efficacy will then be evaluated in newly-diagnosed cancer patients, in combination with current appropriate treatments.
I’d like to take this opportunity to thank my team at ARU, Chris Parris and David Butcher, and our research collaborators at Medannex and Brighton and Sussex Medical School.
I dedicate this work to my greatest supporter and motivator, my dad.
Read more on the ARU website.
Article link.
Clinical trial info.”
Source: Hussein Al Ali/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023